Abstract: Provided are various embodiments relating to caninized TNF? antibodies and caninized NGF antibodies. Such antibodies can be used in methods to treat canines with inflammatory conditions, such as inflammatory bowel disease and/or in methods to treat canines with pain, such as osteoarthrititic pain, back pain, cancer pain, and/or a neuropathic pain.

Abstract: An aqueous treating medium may include water; an acid selected from the group consisting of: HCl, HBr, HNO3, H2SO4, H2SO3, H3PO4, H3PO2, HOAc, citric acid, tartaric acid, ascorbic acid, EDTA, methanesulfonic acid, toluenesulfonic acid, and combinations thereof, wherein a concentration of the acid in the aqueous treating medium is from 0.5 M to 1.5 M; a salt, wherein a concentration of the salt in the aqueous treating medium is from greater than 0 M to 2 M; a fluoride-containing compound selected from the group consisting of: HF, NaF, NH4HF2, and combinations thereof, wherein a concentration of the fluoride-containing compound in the aqueous treating medium is from 0.026 M to 0.26 M; and silica, wherein the aqueous treating medium is saturated with silica.

Abstract: A method for facilitating employee selection of one or more health insurance products includes displaying specific defined contribution amounts for health insurance products; receiving, from the user, input corresponding to selection of a health insurance product; displaying, to the user, information regarding the selected insurance product including an estimated cost of a plan including the selected health insurance product, a coupon amount the cost of the plan will be discounted based on a specific defined contribution amount for the class of the selected health insurance product, a lump sum defined contribution amount the cost of the plan will be discounted, and an estimated monthly cost after the coupon amount and lump sum defined contribution amount are applied.

Abstract: Increase propane dehydrogenation activity of a partially deactivated dehydrogenation catalyst by heating the partially deactivated catalyst to a temperature of at least 660° C., conditioning the heated catalyst in an oxygen-containing atmosphere and, optionally, stripping molecular oxygen from the conditioned catalyst.

Abstract: Increase propane dehydrogenation activity of a partially deactivated dehydrogenation catalyst by heating the partially deactivated catalyst to a temperature of at least 660° C., conditioning the heated catalyst in an oxygen-containing atmosphere and, optionally, stripping molecular oxygen from the conditioned catalyst.

Abstract: Increase propane dehydrogenation activity of a partially deactivated dehydrogenation catalyst by heating the partially deactivated catalyst to a temperature of at least 660° C., conditioning the heated catalyst in an oxygen-containing atmosphere and, optionally, stripping molecular oxygen from the conditioned catalyst.

Abstract: The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.

Abstract: Increase propane dehydrogenation activity of a partially deactivated dehydrogenation catalyst by heating the partially deactivated catalyst to a temperature of at least 660° C, conditioning the heated catalyst in an oxygen-containing atmosphere and, optionally, stripping molecular oxygen from the conditioned catalyst.

Abstract: The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.

Abstract: A supported catalyst and process for dehydrogenating a hydrocarbon, the catalyst comprising a first component selected from the group consisting of tin, germanium, lead, indium, gallium, thallium, and compounds thereof; a second component selected from the group consisting of metals of Group 8 of the Periodic Table of the Elements and compounds thereof, and a support comprising alumina in the gamma crystalline form. The catalysts are especially active and efficient when employed in concurrent flow in a dehydrogenation reactor having an average contact time between the hydrocarbon and catalyst of from 0.5 to 10 seconds.

Abstract: Thermal transfer garments and methods are provided. In an embodiment, a glove comprises a glove portion, a thermal transfer portion attached to the glove portion, a pocket in the thermal transfer portion proximate a user's inner wrist and forearm, the pocket including an opening, an inner surface and an outer surface, and fasteners to releasably secure the glove portion and the thermal transfer portion to the user's person.

Abstract: The invention provides breathable laminated articles, preferably free from harmful halogens and plasticizers, which can be constructed and arranged to be usable for any application, such as wallcoverings, where breathability and being free from harmful halogens and/or plasticizers is advantageous. For example, the breathable laminated article can be made from a non-woven, breathable backing layer of material, the backing layer having a plurality of microprojections on a first side, coupled along the first side to a top layer, where the top layer may or may not be breathable, to form an assembly. This assembly has at least one variation formed in the level of the surface of the first side of the first layer, wherein the variation in level is formed such that the microprojections penetrate at least a portion of the top layer to form microapertures that improve the breathability of the top layer.

Abstract: Protective laminates are provided that include (a) a layer that is breathable and highly impermeable to chemicals to a degree that is subject to reduction upon flexing of the highly impermeable layer alone; and (b) a breathable non-textile layer attached to the highly impermeable layer, the non-textile layer mitigating the reduction in the impermeability of the highly impermeable layer if the laminate is flexed. The laminates may, for example, be attached to textiles and used in protective fabrics.

Abstract: A supported catalyst and process for dehydrogenating a hydrocarbon, the catalyst comprising a first component selected from the group consisting of tin, germanium, lead, indium, gallium, thallium, and compounds thereof; a second component selected from the group consisting of metals of Group 8 of the Periodic Table of the Elements and compounds thereof, and a support comprising alumina in the gamma crystalline form. The catalysts are especially active and efficient when employed in concurrent flow in a dehydrogenation reactor having an average contact time between the hydrocarbon and catalyst of from 0.

Abstract: The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.

Abstract: A medication delivery system (20) having features of the present invention comprises a medical container (26) holding a prescribed medication (27) to be delivered to a patient, a tag 24 adapted to be worn by the patient, a handheld computing device (22), and an electronic medication delivery device (30). Data on the medication (27) is contained in a first label (28) on the medication container (27). The first label (28) also contains the instruction on how the medication is delivered to the patient, including the appropriate settings for an electronic medication delivery device for delivering the medication to the patient. Patient data is contained in a second label (29) on the tag (24) worn by the patient. The medication data, medication delivery instruction, and patient data are provided in machine readable formats. The handheld computing device (22) reads the medication data and the medication delivery instruction on the medication container (26) and the patient data on the patient tag (24).

Abstract: Protective laminates are provided that include (a) a layer that is breathable and highly impermeable to chemicals to a degree that is subject to reduction upon flexing of the highly impermeable layer alone; and (b) a breathable non-textile layer attached to the highly impermeable layer, the non-textile layer mitigating the reduction in the impermeability of the highly impermeable layer if the laminate is flexed. The laminates may, for example, be attached to textiles and used in protective fabrics.

Abstract: A system and method for managing containerized freight is disclosed. The system generates a 3-D view of a containerized freight terminal that is rendered on a display. The 3-D view includes rendered scale models of all the containers, vessels, buildings and equipment within the freight yard and according to stored information relating to such. The rendered 3-D view is updated as changes are made to the stored information and according to user input related to the desired point of view and perspective. The rendered scale models may be selectively visually coded or displayed according to pre-determined criteria.

Abstract: Products and methods directed to multilayer upholstery are disclosed. Such upholsteries can be used as a furniture covering or in other covering applications. In many instances, the multilayer upholstery comprises three layers: a clear, cross-linked urethane layer, a textile layer and a polymeric layer between and coupled to the clear and textile layers. Additionally, the multilayer upholstery can contain a solid color or printed pattern. The printed pattern can be derived from a printed textile surface or a print film disposed as one of the layers. Methods for modifying the layers to yield antimicrobial properties, chemical resistance and adhesive bonding between layers are also disclosed.

Abstract: A method and apparatus for the distribution of electronic media content for distribution to employees of a subscriber. The system includes an electronic display for displaying selected electronic media content that may be selected, modified and/or generated by the subscriber. The system allows for dramatically increased subscriber control of the media content presented as well as for increased security for any confidential media content to be presented on the customer display. The system further provides for individual control of multiple displays that may be located in differing geographic locations while at the same time providing for ease of information management.